Healthcare
India's Netmeds gets $45m Series C round
Indian online drug marketplace operator Netmeds has received a $45 million Series C funding round with participation from Russian venture capital investor Sistema Asia Fund.
Qiming, Hillhouse back China's Jacobio Pharma
Chinese drug maker Jacobio has secured a $55 million Series C funding round led by Qiming Venture Partners and Hillhouse Capital, with participation from Prudence Investment Management.
Adamantem to buy Australia's Zenitas Healthcare
Adamantem Capital has agreed to buy Australia-based Zenitas Healthcare in a deal worth approximately A$122 million ($88 million), including debt. It is working with Liverpool Partners, an investment and advisory firm with extensive experience in healthcare.
VinaCapital launches VC arm, agrees three deals
Vietnam’s VinaCapital has launched a $100 million VC unit and confirmed its first two domestic investments. Separately, the private equity firm has committed $25 million to a local hospital operator.
GIC leads $85m Series B for China's Harbour BioMed
Harbour BioMed, a China-based biopharmaceutical company focused on treatments for cancer and autoimmune disorders, has raised an $85 million Series B round led by Singapore’s GIC Private.
GPs support $590m investment in take-private target China Biologic
China Biologic Products, a US-listed biopharmaceuticals player that was subject to two take-private offers, said it was set to raise $590 million by issuing new shares to investors including Centurium Capital, CITIC Capital, and Hillhouse Capital.
China’s GL commits $12.5m to UK-listed healthtech platform
GL Capital, a healthcare-focused GP based in China, has invested GBP9.75 million ($12.5 million) in UK-listed health technology platform Oxford BioDynamics (OBD) as part of a larger partnership aimed at expansion in China.
CDH-backed Mabpharm files for Hong Kong IPO
Mabpharm, a China-based biopharmaceutical company backed by CDH Investments, has filed for an IPO in Hong Kong, the latest in a growing number of proposed listings under new rules that allow biotech companies with no revenue or profits to go public.
Sequoia India closes sixth fund at $695m
Sequoia Capital India has closed its sixth fund at $695 million, surpassing a target range of $625-675 million.
China’s Ascentage Pharma files for HK IPO
Ascentage Pharma, a Chinese biopharmaceutical company with several private equity backers, has filed for an IPO in Hong Kong.
China Biologic Products receives competing take-private offer
US-listed China Biologic Products has received a buyout offer worth $3.9 billion from a consortium including former CEO David Gao and CDH Investments. It follows a $3.6 billion bid last month by CITIC Capital.
Matrix raises $300m for third India fund
Matrix Partners has raised $300 million for its third India-focused venture capital fund, which will back companies in sectors including consumer and enterprise technology and financial technology.
Chinese online drugstore operator targets US listing
Chinese online pharmacy operator 111 Inc, which counts ClearVue Partners, Verlinvest and BioVeda Capital among its investors, has filed for an IPO in the US.
Blackstone to invest $400m in Hong Kong-listed HEC Pharm
The Blackstone Group has agreed to invest $400 million in YiChang HEC Changjiang Pharmaceutical (HEC Pharm), a Chinese drug developer listed in Hong Kong, through a convertible bond issuance.
Golden Equator launches Brunei accelerator
Singapore’s Golden Equator has launched an accelerator in Brunei aimed at helping local small to medium-sized enterprises (SME) expand across Southeast Asia.
Wattle Hill bids for Australia's Capilano Honey, targets China growth
Wattle Hill RHC, a private equity firm that targets Australian businesses with products and services that appeal to Chinese consumers, has won board approval for a A$189.7 million ($138 million) privatization of honey producer Capilano Honey.
True North to acquire orthopedics division of India’s Glenmark
True North has agreed to acquire the Indian orthopedics and pain management business of drug maker Glenmark Pharmaceuticals at a valuation of INR6.4 billion ($91.8 million).
PE-backed Chinese healthtech firms to merge
China-based healthcare platforms Tencent Doctorworks and Xingren.com, both of which have several private equity and venture capital investors, have agreed to merge.
India's Epiq closes first three investments
Epiq Capital, an India-focused private equity firm founded by Matrix Partners India co-founder Rishi Navani, has completed its first three investments in eyewear retailer Lenskart Solutions, financial technology company Mswipe, and online home rental...
Yunfeng records $2.5b final close on third China fund
Yunfeng Capital, a Chinese private equity firm established by Jack Ma and David Yu, founders of Alibaba Group and Target Media, respectively, has raised $2.5 billion for its third US dollar-denominated fund.
China's CureGenetics gets $17m Series A round
Qiming Venture Partners has led a $17 million Series A funding round for Chinese biotechnology company CureGenetics.
Decheng leads Series C for China's Impact Therapeutics
Chinese biopharmaceuticals developer Impact Therapeutics has raised $30 million in Series C funding from a group of investors led by Decheng Capital.
Actis confirms $150m exit from China diagnostics business
Actis has confirmed that it made a full exit from Chinese in vitro diagnostics (IVD) business Beijing Chemclin Biotech, also known as Kemei Biotechnology, for $150 million.
China's Kemei Biotechnology raises $294m round
Legend Capital and Huaxing Healthcare Fund – a private equity arm of financial advisor China Renaissance – have led a RMB2 billion ($294 million) investment in Beijing Kemei Biotechnology, a Chinese in vitro diagnostics business.